Wikipedia -WSS

Wikipedia

author：focus 2025-10-02 21:05:14 - browse：316

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： States increasingly look to regulate hospital facility fees

WSS

Medical experts are missing from AI regulatory conversations

Crowdfunding for unproven stem cell procedures spreads misinformation

Security flaws in third

DOJ, FTC to increase scrutiny of all types of health care mergers

Fatty liver disease was alleviated by Lilly’s ‘triple

TikTok cracks down on users posting about weight loss drugs

hotspot

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Virginia high school admissions case could be legal follow

States increasingly look to regulate hospital facility fees

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medical experts are missing from AI regulatory conversations

Medical records are filled with copy

TikTok cracks down on users posting about weight loss drugs

Bright Health sells Medicare Advantage business to Molina

States increasingly look to regulate hospital facility fees

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Undocumented workers face uncertainty as immigration law takes effect in Florida

leisure time

Use doctors trained outside the U.S. to ease the physician shortage

Lindsay Lohan welcomes 1st child with husband Bader Shammas

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Couple fighting to bring baby home from Mexico are finally reunited

Medical experts are missing from AI regulatory conversations

entertainment

hotspot

hotspot

hotspot